Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1)
Eton is testing an old medicine for a new illness. Watch if early patient results show the treatment is safe and works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.